3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
2
Recurrence
1
Non-Small Cell Lung Cancer ALK-positive
1
Neurofibromatosis 1
1
Neoplasm Metastasis
1
Meningeal Carcinomatosis
1
Hereditary Sensory and Autonomic Neuropathies
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
1
Advanced Non-Small Cell Lung Cancer
1
ALK Positive Non-small Cell Lung Cancer
1
Interventions
ruxolitinib
9
fludarabine phosphate
8
fludarabine
8
Whole-Body Irradiation
8
Specimen Handling
7
Cytarabine
7
Cyclophosphamide
7
Mycophenolic Acid
6
Tacrolimus
5
Injections
5
Busulfan
5
Biopsy
5
Azacitidine
5
Stem Cell Transplantation
4
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
CPX-351
4
venetoclax
3
luspatercept
3
decitabine and cedazuridine drug combination
3
Liposomes
3
Idarubicin
3
Daunorubicin
3
Cyclosporine
3
Blood Specimen Collection
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
selinexor
2
nilotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
lorlatinib
×
90 days
×
Clear all
No trials found.